Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2018
Statement from FDA Commissioner on the FDA’s new effort for developing and class labelling of in vitro companion diagnostics for classes of oncology therapeutic products
6 December 2018 - One challenge we face right now, when it comes to developing diagnostics that can help target ...
Posted by Michael Wonder on 04 Dec 2018
FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care
4 December 2018 - The U.S. FDA today took a significant step forward in driving the efficient development of novel diagnostic ...
Posted by Michael Wonder on 15 Nov 2018
'Death sentence': One-in-a-million rare cancers get the 'sorting hat' treatment
13 November 2018 - For people with the rarest of cancers, the hope of survival or an effective treatment can ...
Posted by Michael Wonder on 03 Sep 2018
Medicare-funded cancer genetic tests: a note of caution
3 September 2018 - Clinicians need appropriate education and support in keeping pace with the genomics revolution. ...
Posted by Michael Wonder on 04 Jun 2018
Rule out chemotherapy for early breast cancer - but first take a $5,000 test
4 June 2018 - There is good news for women with early breast cancer, but for Australians it comes at ...
Posted by Michael Wonder on 15 Apr 2018
Cutting-edge cancer drug hobbled by diagnostic test confusion
9 April 2018 - Physicians struggle to identify which patients are likely to respond to a recently approved therapy. ...
Posted by Michael Wonder on 20 Mar 2018
DNA on drugs: how genetic tests could make prescriptions more precise
16 March 2018 - It’s well known that different people can react differently to the same drug, with some patients feeling ...
Posted by Michael Wonder on 18 Mar 2018
CMS finalises coverage of Next Generation Sequencing tests, ensuring enhanced access for cancer patients
16 March 2018 - A new opportunity for cancer patients as advanced diagnostic laboratory tests now have expanded Medicare coverage. ...
Posted by Michael Wonder on 19 Feb 2018
August 2018 PBAC special meeting
19 February 2018 - Options for listing of pan-tumour indications for PDL-1 cancer immunotherapies on the PBS. ...
Posted by Michael Wonder on 07 Jan 2018
Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers
4 January 2018 - This study evaluated the cost-effectiveness of BRCA testing in Australian women with breast cancer, and cascade ...
Posted by Michael Wonder on 19 Oct 2017
Breast cancer: BRCA study sent to Canada because U.S. thinks women can't handle genetic test results
19 October 2017 - Hundreds of spit samples have been traveling through the mail across the U.S.-Canadian border. Why? The ...
Posted by Michael Wonder on 29 Jul 2017
Concept paper on development and lifecycle of personalised medicines and companion diagnostic
28 July 2017 - Public consultation to end on 31 October 2017. ...
Posted by Michael Wonder on 29 Jun 2017
FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas
29 June 2017 - The U.S. FDA today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first ...
Posted by Michael Wonder on 19 Jun 2017
Australian-first whole genome sequencing and health testing open to public
20 June 2017 - An Australia-first service that combines whole genome sequencing and a comprehensive health assessment could offer individuals ...
Posted by Michael Wonder on 13 Jun 2017
Integrating companion diagnostics into CDR and pCODR reviews
13 June 2017 - In November 2016, CADTH invited stakeholder comments and feedback on a proposed process for the assessment ...